Kong Yujie, Cai Chen, Ling Li, Zeng Li, Wu Meihong, Wu Yanyun, Zhang Wei, Liu Zhong
Clinical Transfusion Research Center, Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, 610052, Chengdu, Sichuan Province, PR China; Key laboratory of transfusion adverse reactions, CAMS, 610052, Chengdu, Sichuan Province, PR China.
Department of Special Clinic, First affiliated hospital, the Second Military Medical University, Shanghai, 200433, Shanghai, PR China; Guanggu District, the Maternal and Child Health Hospital of Hubei Province, 430070, Wuhan, Hubei Province, PR China.
Transfus Apher Sci. 2020 Oct;59(5):102820. doi: 10.1016/j.transci.2020.102820. Epub 2020 May 21.
Because treatment options for coronavirus disease 2019 (COVID-19) are very limited, the use of convalescent plasma has bee explored.
A male centenarian with cough and dyspnea for 2 months was diagnosed with COVID-19. Without effective treatments and with the increased risks of antiviral therapy for the elderly, this patient was given convalescent plasma. The viral load, complete blood count, inflammatory indicators, vital signs, and clinical symptoms were observed before and after COVID-19 convalescent plasma transfusion.
After convalescent plasma transfusion, significant improvement was observed on laboratory indicators and clinical symptoms of the patient. Concurrently, SARS-CoV-2 viral load decreased sharply after the first transfusion (from 2.55 × 104 to 1.39 × 103 copies/mL) and became undetectable after the second transfusion.
With the substantial increase of COVID-19 in recent months,treatment for elderly patients has become restricted in some countries. The successful treatment of this 100-year-old patient using convalescent plasma suggests that we should consider adding convalescent plasma in th management of the elderly.
由于2019冠状病毒病（COVID-19）的治疗选择非常有限，人们已探索使用康复期血浆。
一名患有咳嗽和呼吸困难2个月的男性百岁老人被诊断为COVID-19。由于缺乏有效治疗方法且老年人进行抗病毒治疗的风险增加，该患者接受了康复期血浆治疗。在输注COVID-19康复期血浆前后，观察患者的病毒载量、全血细胞计数、炎症指标、生命体征和临床症状。
输注康复期血浆后，患者的实验室指标和临床症状有显著改善。同时，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒载量在首次输注后急剧下降（从2.55×10⁴降至1.39×10³拷贝/毫升），在第二次输注后变为检测不到。
近几个月来，随着COVID-19病例大幅增加，一些国家对老年患者的治疗受到限制。该100岁患者使用康复期血浆治疗成功表明，我们应考虑在老年患者的治疗中增加康复期血浆治疗。
